Clinical Trial Update: Efficacy of Nilotinib in First or Second Line Treatment of Primary Melanomas Stage III Unresectable Melanomas. [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating nilotinib as a first- or second-line treatment for unresectable Stage III melanoma. The provided snippet does not include trial results…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Nilotinib (nilotinib)

Snippet

Sponsor: Assistance Publique - Hôpitaux de Paris | Conditions: Malignant Skin Melanoma T0, Stage III Melanoma | Phase 2 | Status: UNKNOWN